Immunicum AB Announces Presentations and Participations at Upcoming Conferences in March

GOTHENBURG, Sweden, March 1, 2017 – Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that Carlos de Sousa, MD, CEO of Immunicum, will participate and hold presentations at several upcoming investor and business development conferences.  These meetings include the following:


BIO-Europe Spring
Date: March, 20-22, 2017
Venue: Centre Convencions Internacional, Barcelona, Spain

5th Annual Cancer Biopartnering and Investor Forum
Date: March, 28, 2017
Venue: New York Academy of Science, NYC

Carlos de Sousa will also participate in a panel discussion on “Development Strategies for Early and Late Stage IO Combination Therapies” at 10.35 am EST at the 5th Annual Cancer Biopartnering and Investor Forum


28th Annual Cancer Progress Conference Defined Health
Date: March, 7-8, 2017
Venue: The Westin New York at Time Square, NYC

Jefferies Immuno-Oncology Summit
Date: March, 30, 2017
Venue: Boston Harbor Hotel, Boston, MA

About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage company developing novel immuno-oncology therapies against a range of solid tumors. The Company’s lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body.

For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52

Media Contact
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Ph: +49 89 2424 3494 or + 49 175 571 1562

The Company’s Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31

Keep reading

Immunicum AB: Year-End Report 2016 (July 2016 – December 2016)